Version 1
: Received: 4 September 2024 / Approved: 4 September 2024 / Online: 4 September 2024 (16:05:04 CEST)
How to cite:
Haigh, J. E.; Patel, K.; Rack, S.; Jiménez-Labaig, P.; Betts, G.; Harrington, K. J.; Metcalf, R. The Clinical Utilisation and Duration on Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Preprints2024, 2024090382. https://doi.org/10.20944/preprints202409.0382.v1
Haigh, J. E.; Patel, K.; Rack, S.; Jiménez-Labaig, P.; Betts, G.; Harrington, K. J.; Metcalf, R. The Clinical Utilisation and Duration on Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Preprints 2024, 2024090382. https://doi.org/10.20944/preprints202409.0382.v1
Haigh, J. E.; Patel, K.; Rack, S.; Jiménez-Labaig, P.; Betts, G.; Harrington, K. J.; Metcalf, R. The Clinical Utilisation and Duration on Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Preprints2024, 2024090382. https://doi.org/10.20944/preprints202409.0382.v1
APA Style
Haigh, J. E., Patel, K., Rack, S., Jiménez-Labaig, P., Betts, G., Harrington, K. J., & Metcalf, R. (2024). The Clinical Utilisation and Duration on Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Preprints. https://doi.org/10.20944/preprints202409.0382.v1
Chicago/Turabian Style
Haigh, J. E., Kevin Joseph Harrington and Robert Metcalf. 2024 "The Clinical Utilisation and Duration on Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers" Preprints. https://doi.org/10.20944/preprints202409.0382.v1
Abstract
Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2 and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on efficacy of HER2-directed therapies in SGC. This is a retrospective observational study using anonymised data from commercial compassionate-use access registrations and a privately funded pharmacy prescribing register. Treatment duration was defined as time from drug initiation to treatment discontinuation. Kaplan-Meier analysis of treatment duration was performed using R for windows (v4.3.2). A case report is also provided of an exceptional responder. Eighteen patients were identified who received HER2-directed therapies for HER2-positive recurrent/metastatic SGC, and complete data on treatment duration was available for 15/18. Histology was salivary duct carcinoma in 13/18 patients, adenocarcinoma NOS in 4/18, and carcinoma ex pleomorphic adenoma in 1/18. Median treatment duration was 8.3 months (95% CI: 6.41-not reached) and the range was 1.0-47.0 months. Choice of HER2-directed therapy varied, with ado-trastuzumab emtasine being most common (9/18). At time of analysis, HER2-directed therapy was ongoing for 9/15, discontinued due to disease progression for 4/15, discontinued due to toxicity for 1/15, and 1/15 was discontinued for an unspecified reason. An exceptional responder experienced a complete response with a treatment duration of 47.0 months. This real-world data is comparable to the median PFS observed with HER2-directed therapies in phase II trials and supports the use of HER2-directed therapies in this group.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
